Skip links

Apple’s Worldwide Developer Conference Maps Out Stronger Cross-platform Development

Jump To Section

Apple is known for its flashy consumer product launches, but this week’s 2019 Apple Worldwide Developers Conference (WWDC) demonstrated that the company knows how to impress the developer community too.
Apple’s Worldwide Developer Conference

Apple is known for its flashy consumer product launches, but this week’s 2019 Apple Worldwide Developers Conference (WWDC) demonstrated that the company knows how to impress the developer community too. I thought this year’s conference was one of the more impressive WWDC events of the last two decades, with important new features and products for end consumers and developers alike.

Here are some of the things that really impressed me:

Project Catalyst

Cross-platform development was one of the key themes of the conference, and nowhere is this more apparent than with Project Catalyst, sometimes known by its internal codename of “Marzipan.” Apple announced that the next update of macOS, due out in November, will be able to run iOS apps written for the Apple iPhone and Apple iPad. Catalyst is what makes this possible.

Catalyst incorporates a large set of friendly APIs for cross platform development, which makes it easier, cheaper and faster to bring new apps to the Mac. I suspect this will give a much-needed jumpstart to the Mac app ecosystem, which has been in the doldrums since the rise of mobile platforms like iOS and Android. This opens up the whole world of the top iOS and iPadOS apps to the Mac.


Even more significant is the announcement of SwiftUI, a cross-platform framework that promises to transform the development of apps for Apple platforms. SwiftUI offers a nice abstraction layer for increased productivity, and ease of use, especially for entry level programmers and those building enterprise applications with less custom UI needs.

My first impression is that SwiftUI is highly compositional, easy to read, and simple to learn. Building apps used to be an undertaking of several months. SwiftUI lowers the bar in both the time needed to develop an app and the skill needed, making coding more universally accessible to people. As a developer, I’m just excited to use it. It will make Apple platforms more fun to use.

Currently, iOS apps are typically written in either Swift or an older language called Objective-C or a combination thereof. I predict SwiftUI will become the de facto standard for UI development on Apple platforms very rapidly, expanding adoption of Swift at the same time. SwiftUI will be easier for both entry level and veteran programmers to use.

Such domain-specific language (DSL) paradigms have been around for a while, we even had our own flavor at Altimetrik. Microsoft (UWP, Windows RT), Facebook (React), and Google (Flutter) have all tried similar offerings for mobile app development, but none come close to the scale of Apple iOS and iPadOS. Over a billion devices are ready to consume apps built with SwiftUI, leveraging a fully native stack across 3 platforms; this is in contrast to the more web centric approach Facebook and Google are taking with React and Angular or the more niche mobile offerings such as Flutter or Kotlin. SwiftUI will also have the full backing of Apple as a company, while some of the others seem more like a side play than a major focus.

with Apple

I also think this is huge news. Apple has a reputation for putting privacy as a top focus, and it certainly knows how to build a strong and cohesive user experience. Sign-in with Apple provides a secure, private, and unified interface to sign-in to all app experiences across all Apple platforms. Watch out, Facebook and Google, as this could be a game changer for identity and authentication technology. This actually could be the most disruptive web related news out of WWDC 2019 and will be an interesting space to watch as potential antitrust movements currently surrounding all these companies play out.

Apple Watch

I was impressed with the progress Apple is making. As Watch apps can finally run independently from the iPhone, and Watch apps are even now available in their own Watch oriented App Store, this enables new and exciting use cases, such as more connected experiences with smart homes, connected vehicles (see our own case study with a leading US automaker), more robust retail solutions, true indoor navigation, just to name a few.

Last but not least, there are the new health features of the Apple Watch, which have been growing in both breadth (e.g., activity trends, and period tracker) and depth (e.g. ECG app, CareKit, clinical trials, insurance). With iOS 13, Apple released tons of new APIs for developers to deliver even better health-centric apps and solutions. Look for much more on this from third-party developers in the months to come.

Apple has certainly raised the bar across a number of fronts. Developing on Apple’s platforms will become easier and more efficient. It’s also a win for consumers through improved integration across devices and new and better apps.

Picture of Ignacio Segovia

Ignacio Segovia

Latest Reads


Suggested Reading

Ready to Unlock Your Enterprise's Full Potential?

Adaptive Clinical Trial Designs: Modify trials based on interim results for faster identification of effective drugs.Identify effective drugs faster with data analytics and machine learning algorithms to analyze interim trial results and modify.
Real-World Evidence (RWE) Integration: Supplement trial data with real-world insights for drug effectiveness and safety.Supplement trial data with real-world insights for drug effectiveness and safety.
Biomarker Identification and Validation: Validate biomarkers predicting treatment response for targeted therapies.Utilize bioinformatics and computational biology to validate biomarkers predicting treatment response for targeted therapies.
Collaborative Clinical Research Networks: Establish networks for better patient recruitment and data sharing.Leverage cloud-based platforms and collaborative software to establish networks for better patient recruitment and data sharing.
Master Protocols and Basket Trials: Evaluate multiple drugs in one trial for efficient drug development.Implement electronic data capture systems and digital platforms to efficiently manage and evaluate multiple drugs or drug combinations within a single trial, enabling more streamlined drug development
Remote and Decentralized Trials: Embrace virtual trials for broader patient participation.Embrace telemedicine, virtual monitoring, and digital health tools to conduct remote and decentralized trials, allowing patients to participate from home and reducing the need for frequent in-person visits
Patient-Centric Trials: Design trials with patient needs in mind for better recruitment and retention.Develop patient-centric mobile apps and web portals that provide trial information, virtual support groups, and patient-reported outcome tracking to enhance patient engagement, recruitment, and retention
Regulatory Engagement and Expedited Review Pathways: Engage regulators early for faster approvals.Utilize digital communication tools to engage regulatory agencies early in the drug development process, enabling faster feedback and exploration of expedited review pathways for accelerated approvals
Companion Diagnostics Development: Develop diagnostics for targeted recruitment and personalized treatment.Implement bioinformatics and genomics technologies to develop companion diagnostics that can identify patient subpopulations likely to benefit from the drug, aiding in targeted recruitment and personalized treatment
Data Standardization and Interoperability: Ensure seamless data exchange among research sites.Utilize interoperable electronic health record systems and health data standards to ensure seamless data exchange among different research sites, promoting efficient data aggregation and analysis
Use of AI and Predictive Analytics: Apply AI for drug candidate identification and data analysis.Leverage AI algorithms and predictive analytics to analyze large datasets, identify potential drug candidates, optimize trial designs, and predict treatment outcomes, accelerating the drug development process
R&D Investments: Improve the drug or expand indicationsUtilize computational modelling and simulation techniques to accelerate drug discovery and optimize drug development processes